Albumin-binding arginine deiminase for cancer targeting treatment and detection of arginine

ABSTRACT

The present invention provides a pharmaceutical composition containing albumin-binding arginine deiminase (AAD) fusion protein for treating cancer or other arginine-dependent diseases. The AAD fusion protein can be purified from both soluble and insoluble fractions of crude proteins, it binds to human serum albumin (HSA) or animal serum albumin and has its high activity with longer half life for efficient depletion of arginine in cancer cells. The specific activities of wild-type ADI and AAD fusion protein in the present invention are about 20 and about 19 U/mg (at physiological pH 7.4), respectively. The AAD fusion protein used in the present invention can be used in the treatment of various cancers (e.g. pancreatic cancer, leukemia, melanoma, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer &amp; brain cancer) and curing arginine-dependent diseases. The composition can be used alone or in combination with at least one chemotherapeutic agent to give a synergistic effect on cancer treatment and/or inhibiting metastasis. The AAD fusion protein can also be used as a component for detection and quantitative analysis of arginine in a testing kit for various samples including blood, food and analytical samples.

CROSS-REFERENCE TO RELATED APPLICATION

The present application is a continuation-in-part application of U.S. non-provisional patent application Ser. No. 14/197,236 filed Mar. 5, 2014, which claims benefit from U.S. provisional patent application Ser. No. 61/773,214 filed Mar. 6, 2013, and the disclosure of which are incorporated herein by reference in its entirety.

COPYRIGHT NOTICE/PERMISSION

A portion of the disclosure of this patent document contains material which is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure as it appears in the Patent and Trademark Office patent file or records, but otherwise reserves all copyright rights whatsoever. The following notice applies to the processes, experiments, and data as described below and in the drawings attached hereto: Copyright © 2014-15, Vision Global Holdings Limited, All Rights Reserved.

TECHNICAL FIELD

The present invention describes albumin-binding arginine deiminase (AAD) fusion protein that has been genetically modified to create a material having high activity and long in vivo half-life. The present invention further describes the designs for DNA and protein engineering for creating different AAD fusion proteins. The AAD fusion proteins can be isolated and purified from soluble fraction and insoluble fraction (inclusion bodies) of the crude proteins. The present invention further relates to albumin-binding arginine deiminase-containing pharmaceutical compositions for cancer targeting treatment and curing arginine-dependent diseases in humans and other animals. The AAD fusion protein can also be used as a component in a testing kit for detection of arginine.

BACKGROUND OF THE INVENTION

The incidence of pancreatic cancer, colon cancer, liver cancer, melanoma and cervical cancer in the worldwide population is increasing. Effective treatments for these diseases are urgently needed. In many types of cancer including leukemia, melanoma, pancreatic, colon, renal cell carcinoma, lung, prostate, breast, brain, cervical and liver cancers, the cancer cells are auxotrophic for arginine since they lack of expression of argininosuccinate synthetase (ASS), making these cancers excellent targets for arginine depletion therapy.

Arginine is a semi-essential amino acid for humans and other mammals. It can be synthesized from citrulline via a two step process catalyzed by the urea cycle enzymes argininosuccinate synthase (ASS) and argininosuccinate lyase (ASL). Arginine can be metabolized to ornithine by the enzyme arginase, and ornithine can be converted to citrulline by ornithine carbamoyltransferase (OTC) in the mitochondria. The citrulline can be utilized to synthesize arginine again. Normal cells usually do not require an exogenous supply of arginine for growth because of the abundant catalytic activity of ASS and ASL. In contrast, many types of cancers do not express ASS and therefore are auxotrophic for arginine. Their growth is dependent on arginine solely obtained from blood circulation. Therefore, targeting circulating arginine by using arginine-degrading enzymes is a feasible strategy to inhibit ASS-negative tumor growth [Feun et al., Curr. Pharm. Des. 14:1049-1057 (2008); Kuo et al., Oncotarget. 1:246-251 (2010)].

Arginine can be degraded by arginase, arginine decarboxylase, and arginine deiminase (ADI). Among them, arginine deiminase (ADI) appears to have the highest affinity for arginine (a low K_(m) value). ADI converts arginine to citrulline and ammonia, the metabolites of the urea cycle. Unfortunately, ADI can only be found in prokaryotes e.g. Mycoplasma sp. There are some problems associated with the isolation and purification of ADI from prokaryotes. ADI isolated from Pseudomonas putida fails to exhibit efficacy in vivo because of its low enzymatic activity in neutral pH. ADI produced from Escherichia coli is enzymatically inactive and subsequently requires multiple denaturation and renaturation process which raises the subsequent cost of production.

As the native ADI is found in microorganisms, it is antigenic and rapidly cleared from circulation in a patient. The native form of ADI is immunogenic upon injection into human circulation with a short half-life (˜4 hours) and elicits neutralizing antibodies [Ensor et al., Cancer Res. 62:5443-5450 (2002); Izzo et al., J. Clin. Oncol. 22:1815-1822 (2004)]. These shortcomings can be remedied by pegylation. Among various forms of pegylated ADI, ADI bound with PEG (molecular weight 20,000) via succinimidyl succinate (ADI-PEG 20) has been found to be an efficacious formulation. However, the activity of ADI after pegylation is greatly decreased on the order of 50% [Ensor et al., Cancer Res. 62:5443-5450 (2002)]. The previous attempts to create pegylated ADI resulted in materials that are not homogenous (due to the random attachment of PEG on protein surface Lys residues) and also difficult to characterize and perform quality control during the manufacturing process. Also, PEG is very expensive, greatly increasing the production cost. After the intravenous injection of pegylated ADI in vivo, leakage or detachment of free PEG is observed and the ADI (without PEG) can elicit the immunogenicity problem. Therefore, there is a need for improved cancer-treatment compositions, particularly, improved cancer-treatment compositions that have enhanced activity and in vivo half-life.

SUMMARY OF THE INVENTION

In the present invention, albumin-binding arginine deiminase (AAD) fusion protein has increased its activity and plasma half-life in order to efficiently deplete arginine in cancer cells. Native ADI may be found in microorganisms and is antigenic and rapidly cleared from circulation in a patient. The present invention constructs different AAD fusion proteins with one or two albumin-binding proteins to maintain high activity with longer in vivo half-life (at least 5 days of arginine depletion after one injection). In the present invention, the albumin binding protein in the AAD fusion protein product does not appear to influence its specific enzyme activity but instead appears to increase the circulating half-life. The specific activities of wild-type ADI and AAD fusion protein in the present invention are about 20 and about 19 U/mg (at physiological pH 7.4), respectively. In addition, the AAD fusion protein of the present invention is generally more soluble in most of the solutions than native or wild-type ADI of different organisms. Purification of native or wild-type ADI is also generally more difficult than the AAD fusion protein of the present invention.

In its broadest sense, the present invention provides an albumin-binding arginine deiminase fusion protein comprising a first portion comprising one or two components selected from an albumin-binding domain, an albumin-binding peptide or an albumin-binding protein(s) fused to a second portion comprising arginine deiminase to form the albumin-binding arginine deiminase fusion protein such that the albumin-binding arginine deiminase fusion protein retains the activity of arginine deiminase and is also able to bind serum albumin.

The present invention further relates to albumin-binding arginine deiminase (AAD) fusion protein-containing pharmaceutical compositions for targeted cancer treatment in humans and other animals. The first aspect of the present invention is to construct the modified AAD fusion protein with high activity against cancer cells. The second aspect of the present invention is to purify AAD fusion protein with high purity from both soluble and insoluble fractions of the crude proteins. The third aspect of the present invention is to lengthen the half-life of AAD fusion protein as it can bind to albumin very well in the circulation. The fourth aspect of the present invention is to provide a method of using the AAD fusion protein-containing pharmaceutical composition of the present invention for treating cancer by administering said composition to a subject in need thereof suffering from various tumors, cancers or diseases associated with tumors or cancers or other arginine-dependent diseases. The fifth aspect of the present invention is to use AAD fusion protein as a component in a testing kit for detection of arginine.

The AAD fusion protein of the present invention is also modified to avoid dissociation into albumin-binding protein and ADI such that it becomes more stable and has a longer half-life in circulation. ADI is fused to an albumin-binding domain/peptide/protein in AAD fusion product to extend the plasma half-life and reduce the immunogenicity of the fusion product. Albumin binding domain (ABD) is a peptide that binds albumin in the blood. There are different variants of ABD showing different or improved human serum albumin (HSA) affinities. Different variants of ABD can be constructed and can be fused to ADI. Unlike the naturally occurring ADI, this longer half-life property facilitates the depletion of arginine efficiently in cancerous cells, cancer stem cells and/or cancer progenitor cells.

The pharmaceutical composition containing AAD fusion protein can be used for intravenous (i.v.) injection (for rapid-acting dosage of medication) and intramuscular (i.m.) injection (for fairly rapid-acting and long-lasting dosage of medication). The application of AAD fusion protein in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, melanoma, head and neck cancer, colorectal cancer, lung cancer, breast cancer, prostate cancer, cervical cancer, liver cancer, nasopharyngeal cancer, esophageal cancer and brain cancer. The present invention is directed to AAD fusion proteins, to methods of treating cancer, to methods of treating and/or inhibiting metastasis of cancerous tissue, and to methods of curing arginine-dependent diseases.

The method of the present invention also includes using a combination of different chemotherapeutic drugs and/or radiotherapy with the AAD fusion protein of the present invention to give a synergistic effect on cancer treatment.

In the presently claimed invention, an aspect relates to the use of the AAD fusion protein of the present invention as a component in a testing kit for detection of arginine in different samples (e.g. blood samples from cancer patients, food samples, cell cultures). Said testing kit comprises the AAD fusion protein of the present invention and a color reagent. When a sample is incubated with the AAD fusion protein and the color reagent of the testing kit in appropriate assay conditions, the arginine is converted by the AAD fusion protein into citrulline. The color reagent will be turned into pink color in the presence of citrulline. The presence of citrulline indicates the presence of arginine in the sample and the intensity of the pink color developed in the assay can be used to quantify the concentration of the arginine in the sample by measuring the color intensity of the reaction mixture in a spectrophotometer. The sample can be prepared in solution form before using the testing kit. The concentration of the arginine in the sample can be expressed by the following formula:

one unit of arginine deminase activity=1 μmol of arginine being converted to 1 μmol of citrulline per minute.

In one embodiment, the AAD fusion protein of the present invention has a specific activity of about 19 U/mg at pH 7.4 and 37° C., which is comparable to the activity of wild-type ADI. There are many advantages of using the AAD fusion protein of the present invention over wild-type ADI as enzyme of the testing kit, such as (1) simple production method, (2) longer shelf-life and (3) higher solubility. For wild-type ADI, it is usually insoluble and difficult for purification. For our AAD fusion protein, it can be prepared both soluble and insoluble forms.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the design approach for construction of different AAD fusion proteins with one or two albumin-binding domain/peptide/protein(s) in three-dimensional structure. One or two albumin-binding domain/peptide/protein(s) can be fused to ADI to form the AAD fusion protein. The position of albumin-binding domain/peptide/protein is far from the ADI active site. The albumin-binding domain/peptide/protein can be fused to the N-terminus or/and C-terminus of ADI. The structure in this figure is based on the Mycoplasma arginini ADI structure (Protein Data Bank: 1LXY). (A) Native ADI; (B) AAD fusion protein with two ABD or ABD1; (C) AAD fusion protein with one ABD or ABD1 at N-terminus; (D) AAD fusion protein with one ABD or ABD1 at C-terminus.

FIG. 2 shows the sequence alignment for ADI in some bacterial species including Mycoplasma arginini (SEQ ID No. 23), Lactococcus lactis (SEQ ID No. 24), Bacillus cereus (SEQ ID No. 25) and Bacillus licheniformis (SEQ ID No. 26).

FIG. 3 shows the designs and amino acid sequences for different AAD fusion proteins originated from Mycoplasma arginini (A to E) and AAD fusion protein originated from Bacillus cereus (F).

FIG. 4 shows the creation of AAD fusion protein in two embodiments (A) and (B) by the use of intein-fusion proteins and expressed protein ligation (CBD, chitin binding domain) under the following schemes; (C) C-terminal fusion; (D) N-terminal fusion; (E) Intein-mediated protein ligation.

FIG. 5 shows the plasmid map of the expression vector constructed for producing AAD fusion protein.

FIG. 6 shows the (A) gene map, (B) nucleotide sequence (SEQ ID No. 44) and (C) amino acid sequence (SEQ ID No. 40) of His-ABD-PolyN-ADI. (ADI: the Mycoplasma arginini ADI)

FIG. 7 shows the (A) gene map, (B) nucleotide sequence (SEQ ID No. 45) and (C) amino acid sequence (SEQ ID No. 41) of His-ABD-PolyN-bcADI. (bcADI, the Bacillus cereus ADI)

FIG. 8 shows the expression and purification of AAD fusion protein: (A) AAD is ˜90% soluble when expressed at 20° C. (lanes 2 and 3) and ˜90% insoluble (inclusion body) when expressed at 37° C. (lanes 4 and 5); (B) The purified AAD fusion protein in sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel: lane 1, purified AAD fusion protein (52.8 kDa); lane 2, molecular weight marker.

FIG. 9 shows the isoelectric point of AAD fusion protein in a pH 3-7 IEF protein gel.

FIG. 10 shows the human serum albumin (HSA) binding of AAD. M: marker; Lane 1: HSA only; Lane 2: HSA:AAD ratio=1:1; Lane 3: HSA:AAD ratio=1:5; Lane 4: AAD only; Open Arrow: band of AAD, HSA, or AAD-HSA complexes.

FIG. 11 is a graph showing the dose response of AAD fusion protein on plasma arginine levels in mice. A dose of 100 μg of AAD is sufficient to deplete plasma arginine for at least 5 days.

FIG. 12 shows the effects of administration of AAD fusion protein in total of 10 U per week and/or GEM on (A) tumor size; (B) appearance of the Mia-paca-2 pancreatic cancer xenograft; (C) tumor volume and (D) body weight of the mice.

FIG. 13 shows the effects of administration of AAD fusion protein in total of 10 U per week and/or DTX on (A) tumor size; (B) appearance of the 22Rv1 prostate cancer xenograft and (C) tumor volume of the mice.

FIG. 14 shows the effects of administration of AAD fusion protein in total of 10 U per week of the Jurkat leukemia xenografts on tumor volume of the mice.

DEFINITIONS

The term “cancer stem cell” refers to the biologically distinct cell within the neoplastic clone that is capable of initiating and sustaining tumor growth in vivo (i.e. the cancer-initiating cell).

DETAILED DESCRIPTION OF THE INVENTION

Arginine is a semi-essential amino acid for humans and other mammals. It can be synthesized from citrulline via a two step process catalyzed by urea cycle enzymes argininosuccinate synthase (ASS) and argininosuccinate lyase (ASL). Arginine can be metabolized to ornithine by the enzyme arginase, and ornithine can be converted to citrulline by ornithine carbamoyltransferase (OTC) in the mitochondria. The citrulline can be utilized to synthesize arginine again. Normal cells do not typically require an exogenous supply of arginine for growth because of the abundant catalytic activity of ASS and ASL. In contrast, many types of cancers do not express ASS and are therefore auxotrophic for arginine. Their growth is solely dependent on arginine from circulation. Therefore, targeting circulating arginine by using arginine-degrading enzymes is a feasible strategy to inhibit ASS-negative tumor growth.

Arginine can be degraded by arginine deiminase (ADI). ADI converts arginine to citrulline and ammonia, the metabolites of the urea cycle. Unfortunately, ADI can only be found in prokaryotes e.g. Mycoplasma sp. There are many problems associated with the isolation and purification of arginine deiminase from prokaryotes. ADI isolated from Pseudomonas putida failed to exhibit efficacy in vivo because of its low enzymatic activity in neutral pH. ADI produced from Escherichia coli is enzymatically inactive and subsequently requires multiple denaturation and renaturation process which raised the subsequent cost of production. The plasma half-life of the native form of ADI is short (˜4 hours) upon injection into human circulation [Ensor et al., Cancer Res. 62:5443-5450 (2002); Izzo et al., J. Clin. Oncol. 22:1815-1822 (2004)]. These shortcomings can be partially remedied by pegylation. Among various forms of pegylated ADI, ADI bound with PEG (molecular weight 20,000) via succinimidyl succinate (ADI-PEG 20) has been found to be an efficacious formulation. However, the activity of ADI after pegylation is greatly decreased (by ˜50%) [Ensor et al., Cancer Res. 62:5443-5450 (2002); Wang et al., Bioconjug. Chem. 17:1447-1459 (2006)]. Also, the succinimidyl succinate PEG linker can easily be hydrolyzed and detached from the protein, causing immunogenic problems after a short period of use in the body. Therefore, there is a need for improved cancer-treatment compositions, particularly, improved cancer-treatment compositions with enhanced activity.

ADI isolated from P. putida failed to exhibit efficacy in vivo because it had little enzyme activity at a neutral pH and was rapidly cleared from the circulation of experimental animals. ADI derived from Mycoplasma arginini is described, for example, by Takaku et al, Int. J. Cancer, 51:244-249 (1992), and U.S. Pat. No. 5,474,928. However, a problem associated with the therapeutic use of such a heterologous protein is its antigenicity. The chemical modification of ADI from Mycoplasma arginini, via a cyanuric chloride linking group, with polyethylene glycol (PEG) was described by Takaku et al., Jpn. J. Cancer Res., 84:1195-1200 (1993). However, the modified protein was toxic when metabolized due to the release of cyanide from the cyanuric chloride linking group. In contrast, even for the ADI-PEG20, the PEG linker can easily be hydrolyzed and detached from the protein, causing immunogenic problems after a short period of use in the body. Therefore, there is a need for compositions which degrade non-essential amino acids and which do not have the problems associated with the prior art.

In many types of cancer including melanoma, pancreatic, colon, leukemia, breast, prostate, renal cell carcinoma and liver cancers, cancer cells are auxotrophic for arginine since they lack of expression of argininosuccinate synthetase (ASS), making them excellent targets for arginine depletion therapy. In this invention, albumin-binding arginine deiminase (AAD) fusion proteins have high activity with long half-lives for efficient depletion of arginine in cancer cells.

The size of the monomer for ADI is on the order of 45 kDa and it exists as dimer (on the order of 90 kDa) [Das et al., Structure. 12:657-667 (2004)]. A design for construction of an AAD fusion protein is shown in FIG. 1. One or two albumin-binding domain/peptide/protein(s) with or without linker(s), SEQ ID NO: 46-49, are fused to ADI to form the AAD fusion protein. It is noteworthy that the selection of one or two particular albumin-binding domain/peptide/protein(s) can be made depending upon the type of cancer tissue to be targeted, the desired size and half-life of the resulting fusion protein, and whether a domain or entire protein is selected. Further, the selected albumin-binding material may be the same or different. That is, a protein and a peptide can be fused, two proteins, two domains, a domain and a protein, etc., as long as the resultant molecule retains the activity of the ADI and is also able to bind serum albumin with neither function of one portion of the fusion protein being interfered with by the other portion of the fusion protein. The position of the albumin-binding domain/peptide/protein is far from the active site. The albumin-binding domain/peptide/protein can be fused to the N-terminus or/and C-terminus of ADI. There are different variants of ABD showing different or improved human serum albumin (HSA) affinities. Different variants of ABD can be constructed and can be fused to ADI. Some micro-organisms endowed with ADI (for example Pseudomonas sp) cannot be used, due to their potential pathogenicity and pyrogenicity. The source of ADI can be from, but not limited to, different microorganisms, e.g. Mycoplasma (e.g. Mycoplasma arginini, Mycoplasma arthritidis, Mycoplasma hominis), Lactococcus (e.g. Lactococcus lactis), Pseudomonas (e.g. Pseudomonas plecoglossicida, Pseudomonas putida, Pseudomonas aeruginosa), Streptococcus (e.g. Streptococcus pyogenes, Streptococcus pneumoniae), Escherichia, Mycobacterium (e.g. Mycobacterium tuberculosis) and Bacillus (e.g. Bacillus licheniformis, Bacillus cereus). It is preferred that ADI is cloned from Mycoplasma arginini, Lactococcus lactis, Bacillus licheniformis, Bacillus cereus, thermophilic Aspergillus fumigatus or any combination thereof. Their amino acid sequences with SEQ ID (SEQ ID NO: 23-35) and the sequence alignment for some of the amino acid sequences in FIG. 2 are disclosed herein and also in the literatures [Das et al., Structure. 12:657-667 (2004); Wang et al., Bioconjug. Chem. 17:1447-1459 (2006); Ni et al., Appl. Microbiol. Biotechnol. 90:193-201 (2011); El-Sayed et al., Biotechnol Prog. 31(2):396-405 (2015)], where the disclosure of the literatures are incorporated herein by reference in their entirety.

The design and amino acid sequence for (A) native Mycoplasma arginini ADI protein (SEQ ID NO: 23), (B) different AAD fusion proteins originated from the Mycoplasma arginini ADI (SEQ ID NO: 36-40) and (C) AAD fusion protein originated from the Bacillus cereus ADI (SEQ ID NO: 41) are shown in FIG. 3. Different AAD fusion proteins are successfully constructed. A linker is inserted between the albumin-binding protein and ADI in the AAD fusion protein in these embodiments.

On the other hand, a novel AAD fusion protein is also created by the use of intein-fusion proteins and expressed protein ligation (FIG. 4). The novel AAD fusion protein can be formed (1) by reacting the ADI having a N-terminal cysteine residue with a reactive thioester at C-terminus of the ABD, or (2) by reacting the ABD having a N-terminal cysteine residue with a reactive thioester at C-terminus of the ADI so that the ADI and the ABD are linked by a covalent bond. In FIG. 4E, ADI with N-terminal cysteine residue reacts with reactive thioester at the C-terminus of ABD. The thioester tag at the C-terminus of ABD, and an α-cysteine at the N-terminus of ADI are required to facilitate protein ligation. These fragments are produced using a pTWIN1 vector (New England Biolabs) according to the manufacturer's manual. In particular, the gene coding for the ABD-Intein-CBD fusion protein is synthesized and it is cloned into the vector under the control of T7 promoter for expression in E. coli (FIG. 4C). The ABD-Intein-CBD fusion protein produced binds to chitin in a column. The amino acid sequence of ABD-Intein-CBD (SEQ ID NO: 42) is shown in FIG. 4A. After thiol-inducible cleavage and elution from the column, the ABD with reactive thioester at its C-terminus is obtained (FIG. 4C). On the other hand, the gene coding for the CBD-Intein-ADI fusion protein is synthesized and cloned into the vector under the control of the T7 promoter for expression in E. coli (FIG. 4D). The CBD-Intein-ADI fusion protein produced binds to chitin in a column. The amino acid sequence of the CBD-Intein-ADI (SEQ ID NO: 43) is shown in FIG. 4B. After cleavage at pH 7 and 25° C., and elution from the column, the ADI with α-cysteine at its N-terminus is obtained (FIG. 4D). Finally, the AAD fusion protein is produced by the protein ligation reaction as shown in FIG. 4E.

Importantly, AAD fusion proteins can be produced and purified in a convenient manner. For example, an AAD fusion protein is successfully expressed and purified from E. coli both in soluble fraction and insoluble fraction, and this result is shown in FIG. 8. Furthermore, FIG. 8 shows the purified AAD fusion protein analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The size of the purified AAD fusion protein is determined as 52.8 kDa. The isoelectric point of wild-type ADI is 4.7 and the purified AAD fusion protein is about 5.2 (as shown in FIG. 9).

The pharmaceutical composition of the present invention contains AAD fusion protein with high activity for depleting arginine in tumor cells for cancer treatment. The specific activity of the purified AAD fusion protein is found to be similar to that of the wild-type ADI. The inhibitory effect of the AAD fusion protein on a panel of human cancer cell lines is therefore examined using MTT assay. Different cancer cells are seeded in 96-well plates and allowed to grow for 24 h for acclimatization. The cells are then incubated with 0-10 μg/ml of AAD for 72 hours. IC₅₀ is the half maximal inhibitory concentration, that is, it represents the concentration of AAD fusion protein that is required for 50% inhibition of a cancer cell line. The IC₅₀ is a measure of the effectiveness of a drug. The IC₅₀ of AAD fusion protein (amino acid sequence is shown in SEQ ID NO: 40, FIG. 3E) for different cancer cell lines (human melanoma, A375 & SK-mel-28; human colorectal cancer, HCT116; human pancreatic cancer, Pancl & Mia-paca-2; human liver cancer, Sk-hep1; human cervical cancer, C-33A; human breast cancer, MDA-MB-231; human prostate cancer, 22Rv1; and human leukemia, Jurkat) is shown in TABLE 1.

TABLE 1 Cancer cell line IC₅₀ of AAD (argininosuccinate synthetase-negative, ASS^(−ve)) (μg/ml) A375 (human melanoma) 0.104 SK-mel-28 (human melanoma) 1.92 PancI (human pancreatic cancer) 0.043 Mia-paca-2 (human pancreatic cancer) 0.010 Sk-hep1 (human liver cancer) >10 C-33A (human cervical cancer) 0.058 HCT116 (human colorectal cancer) 0.211 MDA-MB-231 (human breast cancer) 0.173 22Rv1 (human prostate cancer) 0.235 Jurkat (human leukemia) 0.379

For the albumin binding study, the present invention has demonstrated successfully that the engineered AAD fusion protein can bind to human serum albumin (HSA) or other animal serum albumin similar to HSA. FIG. 10 shows that the AAD fusion protein (amino acid sequence is shown in SEQ ID NO: 40, FIG. 3E) binds to HSA readily. AAD is incubated with the indicated molar ratio of HSA for 60 min at room temperature as shown in FIG. 10, lanes 1-4. After incubation, samples are subject to native polyacrylamide gel (10%). Lane 2 shows a partial binding of HSA in a 1:1 ratio while a complete binding of HSA is observed in a 1:5 (HSA:AAD) ratio in lane 3. At a mole ratio of 1:5 or 1:1 (i.e. lane 3 or 2 in FIG. 10), the formation of the HSA-AAD complex forms (˜100-110 kDa) according to the construct of FIG. 1 using the linker molecule design. A band with molecular weight ˜100 kDa representing the AAD-HSA complexes (indicated with an open arrowhead) is clearly observed in lane 3. It is expected that the circulating half-life of AAD fusion protein in the blood is increased by the non-covalent HSA-AAD complex formation. Therefore, a long-lasting version of AAD fusion protein has been successfully created.

No commercial products show high efficacy when compared to the AAD fusion protein-containing pharmaceutical composition prepared in this invention. For uses in cancer treatment, the AAD fusion protein-containing pharmaceutical composition of the present invention serves as an anti-cancer agent to deplete the arginine in tumor tissues. AAD fusion protein is a good candidate to be used in combination with other molecular targeting or cytotoxic agents.

The AAD fusion protein in the present invention can also be used as a component in a testing kit for detection of arginine in different samples. AAD has a small Km value; it indicates the high affinity for the substrate (arginine). Therefore, the rate will approach the maximum reaction rate more quickly. The AAD fusion protein can be used to testing arginine level (1) in cancer patients, (2) in a food sample, and (3) in cell culture.

EXAMPLES

The following examples are provided by way of describing specific embodiments of this invention without intending to limit the scope of this invention in any way.

Several of the Examples below relate to methods of making an albumin-binding arginine deiminase fusion protein. Various techniques can be used including cloning and intein-mediated protein ligation. As used herein, the term “cloning” is broadly used and comprises constructing a fusion gene coding for the albumin-binding arginine deiminase fusion protein, inserting the fusion gene into a vector, inserting the vector into a host organism and expressing a protein that includes an albumin-binding arginine deiminase fusion protein. Numerous variants on this technique can be performed and still fall within the cloning contemplated by the present invention.

Example 1 Construction of the Gene Coding for Albumin-Binding Domain/Peptide/Protein (ABD)

The gene coding for ABD is constructed by two rounds of PCR. In the first round, the PCR reaction mixture (total volume of 25 μl) contains the following materials:

1×iProof PCR buffer (Bio-Rad)

50 μM dNTP mixture

0.5 unit of iProof DNA Polymerase (Bio-Rad)

10 nM of each of the following oligos

ABD-F1 forward primer (SEQ ID NO: 01): 5′-CATGATGCGAATTCCTTAGCTGAAGCTAAAGTCTT AGCTAACAGAGAACT-3′ ABD-R2 reverse primer (SEQ ID NO: 02): 5′-TAGTCACTTACTCCATATTTGTCAAGTTCTCTGTT AGCTAAGACTTTAGC-3′ ABD-F3 forward primer (SEQ ID NO: 03): 5′-GAACTTGACAAATATGGAGTAAGTGACTATTACAA GAACCTAATCAACAA-3′ ABD-R4 reverse primer (SEQ ID NO: 04): 5′-TACACCTTCAACAGTTTTGGCATTGTTGATTAGGT TCTTGTAATAGTCAC-3′ ABD-F5 forward primer (SEQ ID NO: 05): 5′-GCCAAAACTGTTGAAGGTGTAAAAGCACTGATAGA TGAAATTTTAGCTGC-3′ ABD-R6 reverse primer (SEQ ID NO: 06): 5′-AGCTACGATAAGCTTAAGGTAATGCAGCTAAAATT TCATCTATCAGTG-3′ The following PCR program is used: 98° C. 30 s; 20 cycles of {98° C. 10 s, 50° C. 20 s, 72° C. 20 s}

In the second round of PCR, the PCR mixture (total volume of 50 μl) contains the following materials:

1×iProof PCR buffer (Bio-Rad);

50 μM dNTP mixture;

1 μl of PCR reactant as DNA template from the first round;

1 unit of iProof DNA Polymerase (Bio-Rad);

200 nM of each of the following oligos:

ABD-F7 forward primer (SEQ ID NO: 07): 5′-CATGATGCGAATTCCTTAGCTGAAGCTAAAGTCTT AGCTAACAGAGAACT-3′ ABD-R8 reverse primer (SEQ ID NO: 08): 5′-AGCTACGATAAGCTTAAGGTAATGCAGCTAAAATT TCATCTATCAGTG-3′

The following PCR program is used:

98° C. 30 s; 35 cycles of {98° C. 10 s, 60° C. 20 s, 72° C. 20 s}; 72° C. 5 min

A PCR product containing the DNA sequence of ABD (169 bp) is obtained and purified by Qiagen DNA Gel Extraction Kit for cloning purpose.

Example 2A Construction of the Fusion Gene Coding for the AAD Fusion Protein

In the first PCR, the PCR mixture (total volume of 50 μl) contains the following materials:

1×iProof PCR buffer (Bio-Rad);

50 μM dNTP mixture;

25 ng of Mycoplasma arginini genomic DNA;

1 unit of iProof DNA Polymerase (Bio-Rad);

200 nM of each of the following oligos:

ADINde-F forward primer (SEQ ID NO: 09): 5′-ATCGATCGATGTCTGTATTTGACAGTAAATTTAAAG G-3′ ADIhis-R reverse primer (SEQ ID NO: 10): 5′-AGCTAAGGAATTCGCATCATGATGGTGATGGTGGTGG CTACCCCACTTAAC-3′ The following PCR program is used: 98° C. 1 min; 35 cycles of {98° C. 10 s, 50° C. 20 s, 72° C. 40 s}; 72° C. 5 min A PCR product of 1280 bp long is obtained and purified by Qiagen DNA Gel Extraction Kit. After that, the second PCR is performed. The PCR mixture (total volume of 50 μl) contains the following materials: 1×iProof PCR buffer (Bio-Rad);

50 μM dNTP mixture;

10 ng of the 1280 bp PCR product;

10 ng of the 169 bp PCR product;

1 unit of iProof DNA Polymerase (Bio-Rad);

200 nM of each of the following oligos:

ADINde-F forward primer (SEQ ID NO: 11): 5′-ATCGATCGATGTCTGTATTTGACAGTAAATTTAAAG G-3′ ABD-R10 reverse primer (SEQ ID NO: 12): 5′-AGCTACGATAAGCTTAAGGTAATGCAGCTAAAATTT CATCTATCAGTG-3′ The following PCR program is used: 98° C. 1 min; 35 cycles of {98° C. 10 s, 50° C. 20 s, 72° C. 45 s}; 72° C. 5 min

A PCR product of 1428 bp is obtained and purified by Qiagen DNA Gel Extraction Kit. Then it is digested with restriction enzymes NdeI and HindIII, and ligated to plasmid pREST A (Invitrogen) that is predigested with the same enzymes. The ligation product is then transformed into E. coli BL21 (DE3) cells. The sequence of the constructed fusion gene is confirmed by DNA sequencing.

Example 2B Cloning of His-ABD-PolyN-ADI

The construction of His-ABD-PolyN-ADI (SEQ ID NO: 40, in FIG. 3E) is done by two steps of overlapping PCR, the PCR fragment obtained from the last step is inserted into the vector pET3a between the NdeI and BamHI sites. The gene map, nucleotide sequence and amino acid sequence of His-ABD-PolyN-ADI are shown in FIG. 6.

Primers involved in construction of His-ABD-PolyN-ADI:

hisABDNde-F forward primer (SEQ ID NO: 13): 5′-GGAGATATACATATGCATCATCACCATCACCATGATGAAG CCGTGGATG-3′ ABDnn-R1 reverse primer (SEQ ID NO: 14): 5′-TTGTTATTATTGTTGTTACTACCCGAAGGTAATGCAGCTA AAATTTCATC-3′ ABDn-R2 reverse primer (SEQ ID NO: 15): 5′-AGAACCGCCGCTACCATTGTTATTATTGTTGTTACTACCC GA-3′ ADln-F forward primer (SEQ ID NO: 16): 5′-AATAATAACAATGGTAGCGGCGGTTCTGTATTTGACAGTA AATTTAAAGG-3′ ADIBam-R reverse primer (SEQ ID NO: 17): 5′-TAGATCAATGGATCCTTACCACTTAACATCTTTACGTGAT AAAG-3′

In the first round of PCR, 50 μl of reaction volume containing the known concentration of components are prepared in two PCR tubes. In each of the tubes, dNTP, iProof buffer (BIO-RAD), iProof DNA polymerase (BIO-RAD), primers and DNA template are mixed and added up to 50 μl by ddH₂O. The DNA template used in the reaction is a pET3a vector containing the gene of ADI from Mycoplasma arginini with a removal of an internal NdeI site mutation without altering the protein sequence of the ADI gene.

The two reaction tubes contain the primer mixtures of (A) 10 pmol hisABDNde-F (SEQ ID NO: 13), 0.5 pmol ABDnn-R1 (SEQ ID NO: 14) and 10 pmol ABDn-R2 (SEQ ID NO: 15); and (B) 10 pmol ADIn-F (SEQ ID NO: 16) and 10 pmol ADIBam-R (SEQ ID NO: 17), respectively.

The PCR program is set according to the recommended steps in the manual with an annealing and extension temperature (time) at 50° C. (20 s) and 72° C. (40 s), respectively. The two products generated by PCR with the size of 237 bp and 1278 bp. The products are extracted and applied as template for the next round of PCR.

In the second overlapping step, the reaction mixture is prepared in a similar way to the first round except the template used was the mixture of 1 pmol of the 237 bp PCR product and 1 pmol of the 1278 bp PCR product from the first round PCR. Primers used are changed to 10 pmol hisABDNde-F (SEQ ID NO: 13) and 10 pmol ADIBam-R (SEQ ID NO: 17).

The annealing and extension temperature (time) are 50° C. (20 s) and 72° C. (60 s), respectively. A PCR product with the size of 1484 bp is generated from the reaction. The PCR product is purified and digested with NdeI and BamHI and then ligated into the pre-digested pET3a plasmid. The ligated product is then transformed into E. coli BL21 (DE3) for the production of recombinant protein.

Example 2C Cloning of His-ABD-PolyN-bcADI

The construction of His-ABD-PolyN-bcADI (SEQ ID NO: 41, in FIG. 3F) is done by two steps of overlapping PCR, the PCR fragment obtained from the last step is inserted into the vector pET3a between the NdeI and BamHI sites. The gene map, nucleotide sequence and amino acid sequence of His-ABD-PolyN-bcADI are shown in FIG. 7.

Primers involved in construction of His-ABD-PolyN-bcADI:

hisABDNde-F2 forward primer (SEQ ID NO: 18): 5′-GGAGATATACATATGCATCATCACCATCACCATGATGAAGC CGTGGATG-3′ bcABDnn-R1 reverse primer (SEQ ID NO: 19): 5′-TTGTTATTATTGTTGTTACTACCCGAAGGTAATGCAGCTAA AATTTCATC-3′ bcABDn-R2 reverse primer (SEQ ID NO: 20): 5′-TTTACCGCCGCTACCATTGTTATTATTGTTGTTACTACCCG A-3′ bcADln-F forward primer (SEQ ID NO: 21): 5′-AATAATAACAATGGTAGCGGCGGTAAACATCCGATACATGT TACTTCAGA-3′ bcADIBam-R reverse primer (SEQ ID NO: 22): 5′-TAGATCAATGGATCCCTAAATATCTTTACGAACAATTGGCA TAC-3′

In the first round of PCR, 50 μl of reaction volume containing the known concentration of components are prepared in two PCR tubes. In each of the tubes, dNTP, iProof buffer (BIO-RAD), iProof DNA polymerase (BIO-RAD), primers and DNA template are mixed and added up to 50 μl by ddH₂O. The DNA template used in the reaction is a pET3a vector containing the gene of ADI from Bacillius cereus with a removal of an internal NdeI site mutation without altering the protein sequence of the ADI gene.

The two reaction tubes contain the primer mixtures of (A) 10 pmol hisABDNde-F2 (SEQ ID NO: 18), 0.5 pmol bcABDnn-R1 (SEQ ID NO: 19) and 10 pmol bcABDn-R2 (SEQ ID NO: 20); and (B) 10 pmol bcADIn-F (SEQ ID NO: 21) and 10 pmol bcADIBam-R (SEQ ID NO: 22), respectively. The PCR program is set according to the recommended steps in the manual with an annealing and extension temperature (time) at 50° C. (20 s) and 72° C. (40 s), respectively. The two products are generated by PCR with the size of 237 bp and 1250 bp. The products are extracted and applied as template for the next round of PCR.

In the second overlapping step, the reaction mixture is prepared in a similar way to the first round except the template used is the mixture of 1 pmol of the 237 bp PCR product and 1 pmol of the 1250 bp PCR product from the first round PCR. Primers used are changed to 10 pmol hisABDNde-F2 (SEQ ID NO: 18) and 10 pmol bcADIBam-R (SEQ ID NO: 22).

The annealing and extension temperature (time) are 50° C. (20 s) and 72° C. (60 s), respectively. A PCR product with the size of 1512 bp is generated from the reaction. The PCR product is purified and digested with NdeI and BamHI and then ligated into the pre-digested pET3a plasmid. The ligated product is then transformed into E. coli BL21 (DE3) for the production of recombinant protein.

Example 3 Expression and Purification of the AAD Fusion Protein

(3a) Expression of the AAD Fusion Protein by Shake-Flask Method

For preparing the seed culture, the strain E. coli BL21(DE3) carrying the plasmid encoding the AAD fusion protein (FIG. 5) is cultured in 5 ml of 2×TY medium, 30° C., 250 rpm, overnight. The overnight seed culture (2.5 ml) is added to 250 ml of 2×TY, 37° C., 250 rpm, 2.5 h (until OD₆₀₀≈0.6-0.7). When the OD₆₀₀ reached, IPTG is added to the culture (0.2 mM final concentration). The growth is continued for 22 more hours at 20° C. and then the cells are collected by centrifugation. The cell pellet is resuspended in 25 ml of 10 mM sodium phosphate buffer, pH 7.4. The cells are lysed by sonication.

(3b) Expression of the AAD Fusion Protein by Fermentation Method

For the seed culture, the aliquot of bacteria stock is inoculated into 50 ml of seeding medium (containing 1.5 g of yeast extract and 0.25 g of NaCl) with ampicillin and grown at 30° C. for 16 hr with continuous shaking at 250 rpm. The seed culture is then added to 1.25 L of medium (pH 7.4, containing yeast extract, tryptone, Na₂HPO₄, KH₂PO₄, (NH₄)₂SO₄, glycerol, glucose, MgSO₄.7H₂O, Thiamine-HCl and CaCl₂) supplement with trace element in the BIOSTAT fermentor system and grown at 28° C. Until the OD₆₀₀ of the culture reaches ˜20, IPTG is added to a final concentration of 0.2 mM. The culture is further incubated for 16 hr. During incubation, 500 ml of feeding medium (pH 7.4, containing yeast extract, tryptone, NH₄Cl, (NH₄)₂SO₄, glycerol and MgSO₄.7H₂O) supplement with trace element were applied at 0.5 ml/min. Aeration is regulated in order to maintain 20% of air saturation by varying the speed of stirring from 500 rpm to 2000 rpm. The bacteria are harvested by centrifugation. The cells are lysed by sonication or high pressure homogenizer.

(3c) Purification of the AAD Fusion Protein

The soluble portion is collected after centrifugation. The fusion protein (containing a His tag) is then purified by nickel affinity chromatography. TABLE 2 shows that cultivation temperature is an important factor in affecting the solubility of AAD fusion protein (amino acid sequence is shown in SEQ ID NO: 40, FIG. 3E) obtained from the expression host.

For isolating the soluble fraction of AAD fusion protein, the cell pellet is resuspended in 25 ml of 10 mM sodium phosphate buffer, pH 7.4. The cells are lysed by sonication or high pressure homogenizer. The soluble portion is collected after centrifugation. The AAD fusion protein (contains a His tag or without His tag) is then purified by nickel affinity chromatography and/or ion-exchange columns.

For isolating the insoluble fraction of AAD fusion protein, the cell pellet is resuspended in 25 ml of 20 mM Tris-HCl, pH 7.4, 1% Triton X-100. The cells are lysed by sonication. The insoluble portion (inclusion bodies) is collected by centrifugation. The protein is unfolded by resuspending in 10 ml of 20 mM Tris-HCl, pH 7.4, 6 M Guanidine HCl, and vortexed until it becomes soluble. The protein is refolded by adding the unfolded protein solution drop by drop into a fast stirring solution of 100 ml of 20 mM Sodium phosphate buffer, pH 7.4. The insoluble materials are removed by centrifugation. Salting out of the protein is performed by adding solid ammonium sulphate powder into the supernatant to achieve 70% saturation. The insoluble portion is collected by centrifugation and it is resuspended in 10 ml of 20 mM sodium phosphate buffer. The AAD fusion protein (contains a His tag or without His tag) is then purified by nickel affinity chromatography and/or ion-exchange columns.

TABLE 2 AAD 1 2 3 Cultivation 30 20 37 temperature (° C.) Yield (mg)/ ~0.66 ~12.0 ~7.0 250 ml culture solubility 50% soluble 90% soluble 90% inclusion body IC₅₀ (μg/ml) on 0.10 0.68 0.23 A375 cells “90% inclusion body” means 90% of the AAD fusion protein produced in the bacterial cells are not soluble.

The yield and the enzyme activity of AAD fusion protein from shake-flask method and fermentation method are shown in TABLE 3.

TABLE 3 Activity AAD Yield (mg/L) (U/mg) Shake-flask method ~10 ~9 Fermentation method ~42 ~19

Example 4 Enzyme Activity Assay and Enzyme Kinetics for AAD Fusion Protein

To determine the enzyme activity for wild-type ADI and AAD fusion protein in the present invention, the diacetyl monoxime (DAM)-thiosemicarbazide (TSC) assay for citrulline detection is used. The reaction is shown below.

L-Arginine ^(arginine deiminase(ADI)or AAD fusion) >L-Citrulline+Ammonia

This assay is run by adding sample to a color reagent, which is made by mixing acidic ferric chloride solution with DAM-TSC solution. Briefly, enzyme is incubated with 20 mM arginine, 10 mM sodium phosphate pH 7.4 for 5 min at 37° C. The reaction mixture is heated at 100° C. for 5 mM to develop the color and read at 540 nm (light path=1 cm). A standard curve is constructed using various concentrations of citrulline. One unit of the ADI native enzyme is the amount of enzyme activity that converts 1 μmol of arginine to 1 μmol of citrulline per minute at 37° C. under the assay conditions. The specific activities of wild-type ADI, pegylated ADI (Ensor et al., Cancer Res. 62:5443-5450, 2002) and AAD fusion protein in the present invention are about 20, 15 and 19 U/mg (at pH 7.4, physiological pH), respectively. The specific activities for wild-type ADI and AAD fusion protein at different pH values (in a range from pH 5.5 to 9.5) are also determined, and the optimum pH is at 6.5. Therefore, the results indicate that AAD fusion protein depletes arginine efficiently which is even better than pegylated ADI, as the fusion with albumin-binding protein does not affect enzyme activity of ADI.

The Michaelis constant K_(m) is the substrate concentration at which the reaction rate is at half-maximum, and is an inverse measure of the substrate's affinity for the enzyme. A small K_(m) indicates high affinity for the substrate, and it means that the rate will approach the maximum reaction rate more quickly. For determination of the enzyme kinetics or K_(m) value, the activity of wild-type ADI and AAD fusion protein are measured under different concentration of substrate arginine (2000 μM, 1000 μM, 500 μM, 250 μM, 125 μM, 62.5 μM) at pH 7.4. The measured K_(m) values of the AAD fusion protein shown in FIG. 3E (SEQ ID NO: 40, ADI protein is originated from Mycoplasma arginini) and AAD fusion protein shown in FIG. 3F (SEQ ID NO: 41, ADI protein is originated from Bacillus cereus) are 0.0041 mM and 0.132 mM respectively. The results suggest that the fusion to ABD did not affect the binding affinity of the different AAD fusion proteins to arginine.

Example 5 Cell Proliferation Assay and In Vitro Efficacy of AAD Fusion Protein on Cancer Cell Lines

Culture medium DMEM is used to grow the human melanoma A375 & SK-mel-28 and pancreatic cancer Pancl & Mia-paca-2 cell lines. The EMEM medium is used to culture the human liver cancer SK-hep, cervical cancer C-33A and colorectal cancer HCT116 cell lines. The RPMI-1640 medium is used to culture the human breast cancer MDA-MB-231, prostate cancer 22Rv1 and leukemia Jurkat cell lines. Cancer cells (2-5×10³) in 100 μl culture medium are seeded to the wells of 96-well plates and incubated for 24 hours. The culture medium is replaced with medium containing 0-10 μg/ml of AAD fusion protein. The plates are incubated for an additional 3 days at 37° C. in an atmosphere of 95% air/5% CO₂. MTT assay is performed to estimate the number of viable cells in the culture according to manufacturer's instructions. The amount of enzyme needed to achieve 50% inhibition of cell growth is defined as IC₅₀.

As shown in TABLE 1, the results indicate that AAD fusion protein depletes arginine efficiently and inhibits the growth of various types of human cancer cell lines in in vitro tissue culture studies. For example, human melanoma, human breast cancer, human colorectal cancer, human pancreatic cancer, human liver cancer, human prostate cancer, human leukemia and human cervical cancer, all have low values of IC₅₀ (see TABLE 1), as these cancer types are all inhibited by AAD fusion protein readily. As determined from the in vitro_data, AAD fusion protein would inhibit all cancer types that are arginine-dependent, for example, the argininosuccinate synthetase-negative (ASS^(−ve)) cancers.

Example 6 In Vivo Half-Life Determination of AAD Fusion Protein

Balb/c mice (5-7 weeks) are used in this study and they are allowed to acclimatize for a week before the experiment. Mice (n=3) are separated into four groups and injected with 0, 100, 500 or 1000 μg of AAD fusion protein (SEQ ID NO: 40, FIG. 3E) in 100 μl PBS intraperitoneally, respectively. Blood of each mouse is collected at 0 h and Day 1-7. Sera are obtained after centrifugation. The sera are then deproteinised and analyzed by amino acid analyzer for arginine.

As shown in FIG. 11, AAD fusion protein (SEQ ID NO: 40, FIG. 3E), even at the lowest dosage of 100 μg, depletes plasma arginine efficiently at Day 1, 3 and 5, suggesting that AAD can deplete arginine in vivo efficiently for at least 5 days. The arginine level returns to normal gradually at Day 6 and Day 7 in all treatment groups.

Example 7 In Vivo Efficacy of Weekly Administration of AAD Fusion Protein on HCT 116 Colorectal Cancer Cell Xenografts

Nude balb/c mice (5-7 weeks) are used in this study and they are allowed to acclimatize for a week before the experiment. Mice are inoculated subcutaneously with 2×10⁶ cancer cells in 100 μl of fresh culture medium. Ten days later, the mice are randomly separated into control and treatment group. Control group receives 100 μl PBS and treatment group receives 100 μl AAD fusion protein (amino acid sequence is shown in SEQ ID NO: 40, FIG. 3E) intraperitoneally weekly. Tumor size is measured by caliper and tumor volume is calculated using formula: (length×width²)/2. Blood draw are obtained at Day 5 after each treatment for plasma measurement of arginine.

Example 8 Comparison in In Vivo Efficacy Between Weekly and Biweekly Based Administration of AAD Fusion Protein on HCT 116 Colorectal Cancer Cell Xenograft

Nude balb/c mice (4-6 weeks) are used and they are allowed to acclimatize for a week before the treatment. Mice are inoculated subcutaneously with 2×10⁶ cancer cells in 100 μl PBS. Ten days later, the mice are randomly separated into control and treatment groups. Control group receives 100 μl PBS and treatment group receives 200 μg AAD fusion protein (amino acid sequence is shown in SEQ ID NO: 40, FIG. 3E) in 100 μl PBS intraperitoneally weekly or biweekly. Tumor size is measured by caliper and tumor volume is calculated using formula: (length×width²)/2. In the weekly treatment group, blood draw are obtained at Day 0 and Day 5 of each treatment for plasma measurement of arginine. In the biweekly treatment group, blood draw are obtained just before the first treatment every week for plasma measurement of arginine. After the mice are sacrificed by end of the time course, the tumors are excised and weighed. The plasma arginine levels over the time course in the weekly treatment group are measured.

At Day 5, Day 12 and Day 19, the plasma arginine level is significantly decreased respectively after the weekly administration of the AAD fusion protein. Comparing the plasma arginine levels between Day 0, Day 7 and Day 14, the levels at Day 7 and Day 14 are relatively lower than that at Day 0, revealing that weekly administration of AAD fusion protein can decrease the overall plasma arginine levels over the time course. The tumor size in the weekly treatment group is lower than that in control at the end of the time course, revealing that the weekly administration of AAD fusion protein can reduce the tumor size of the xenograft in the disease mouse model. The difference in the tumor size between control and weekly treatment group is about 20% at Day 30.

The reduction in plasma arginine level is more significant in the biweekly treatment group than that in the weekly treatment group. The biweekly administration of AAD fusion protein does not affect the body weight of the mice over a 35-day time course as compared to the control. In conclusion, biweekly administration of AAD fusion protein in 400 μg per week (16 mg/kg/week/mouse) is more effective in completely suppressing plasma arginine level than weekly administration. Using the conversion of animal doses to human equivalent doses (HED) based on body surface area mentioned in “Guidance for Industry and Reviewers—Estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers (2002)”, human dose of the AAD fusion protein is about 1.3 mg/kg/week.

Example 9 In Vivo Efficacy of AAD Fusion Protein on Mia-Paca-2 Pancreatic Cancer Cell Xenografts

Nude balb/c mice (4-6 weeks) are used and they are allowed to acclimatize for a week before the treatment. Mice are inoculated subcutaneously with 2×10⁶ cancer cells in 100 μl of 1:1 PBS:Matrigel. Matrigel is used to augment the growth of tumors. Two weeks later, the mice are randomly separated into four groups of 4 animals in each group. Mice are intraperitoneally administered with PBS (control), AAD (5 U; twice a week), Gemcitabine, Gem (100 mg/kg; once a week) or AAD+Gem (a combination of both AAD and Gem) in 200 μl PBS. Tumor size is measured by caliper and tumor volume is calculated using formula: (length×width²)/2. Body weight is measured every week. After the mice are sacrificed by end of the time course, the tumors are excised and weighed. The tumor size in all treatment groups is significantly lower than that in control at the end of the time course, revealing that the administration of AAD fusion protein can reduce the tumor size of the xenograft in the disease mouse model (shown in FIG. 12A, 12B, 12C). The difference in the tumor size between control and AAD fusion protein-treatment group is about 60% at Day 28. The treatment groups do not affect the body weight of the mice over a 28-day time course as compared to the control (shown in FIG. 12D).

Example 10 In Vivo Efficacy of AAD Fusion Protein on 22Rv1 Prostate Cancer Cell Xenografts

Nude balb/c mice (4-6 weeks) are used and they are allowed to acclimatize for a week before the treatment. Mice are inoculated subcutaneously with 3×10⁶ cancer cells in 100 μl PBS. Two weeks later, the mice are randomly separated into four groups of 5 animals in each group. Mice are intraperitoneally administered with PBS (control), AAD (5 U; twice a week), Docetaxel, DTX (10 mg/kg; once a week) or AAD+DTX (a combination of both AAD and DTX) in 200 ul PBS. Tumor size is measured by caliper and tumor volume is calculated using formula: (length×width²)/2. Body weight is measured every week. After the mice are sacrificed by end of the time course, the tumors are excised and weighed.

In FIG. 13A, the tumor size in all treatment groups is significantly lower than that in control at the end of the time course, revealing that the administration of AAD fusion protein or docetaxel can reduce the tumor size of the xenograft in the disease mouse model. The difference in the tumor size between control and AAD fusion protein- or DTX-treatment groups are about 55% and 54% at Day 22, respectively. Besides, the combination of AAD fusion protein and DTX-treatment group has a synergistic effect on tumor growth inhibition. Tumor growth of the combination treatment group is inhibited by about 94% when compared to that of the control group. FIG. 13B shows the appearance of the tumor tissues excised from xenografts at Day 22. AAD treatment does not affect the body weight of the mice over a 28-day time course.

Example 11 In Vivo Efficacy of AAD Fusion Protein on Jurkat Leukemia Xenografts

Nude balb/c mice (4-6 weeks) are used and they are allowed to acclimatize for a week before the treatment. Mice are inoculated subcutaneously with 5×10⁶ cancer cells in 100 μl of 1:1 PBS:Matrigel. Matrigel is used to augment the growth of tumors. Since the take rate of this cancer cell line is relatively low, when certain tumor xenograft reaches a suitable size, the tumor is excised and cut into various pieces (˜10 mm³), which are further transplanted to the back of another group of mice subcutaneously. Ten days later, the mice are randomly separated into two groups of 8 animals in each group. Mice are intraperitoneally administered with PBS (control) or AAD (5 U; twice a week) in 200 μl PBS. Tumor size is measured by caliper and tumor volume is calculated using the following formula: (length×width²)/2. Body weight is measured every week. At Day 28, the AAD fusion protein significantly inhibits the tumor growth when comparing to the control group (FIG. 14). The difference in tumor size between AAD fusion protein-treated and control groups becomes more significant at Day 30.

Example 12 Using AAD Fusion Protein in a Testing Kit

AAD fusion protein of the present invention has a small K_(m), indicating the high affinity for the substrate (arginine). Therefore, the rate approaches the maximum reaction rate more quickly. To determine the concentration of arginine in a sample, AAD fusion protein in the present invention, the diacetyl monoxime (DAM)-thiosemicarbazide (TSC) assay for citrulline detection is used. The reaction is as follows:

L-Arginine (of unknown concentration) is converted by AAD fusion protein to form L-Citrulline and Ammonia.

This assay is run by adding sample to a color reagent, which is made by mixing acidic ferric chloride solution with DAM-TSC solution. Briefly, arginine (in the sample, of unknown concentration) is incubated with 2-20 ng of the AAD fusion protein, and 10 mM sodium phosphate pH 7.4 for 5 mM at 37° C. The reaction mixture is heated at 100° C. for 5 mM to develop into pink color and read at 540 nm (light path=1 cm). A standard curve is constructed using various concentrations of citrulline. One unit of the AAD is the amount of enzyme activity that converts 1 μmol of arginine to 1 μmol of citrulline per minute at 37° C. under the assay conditions. This testing kit is very useful for the following applications:

Example 12A Testing Arginine Level in Cancer Patients

For a cancer patient (human or animal), after treated with an arginine depleting drug, the arginine level (concentration) in blood should be very low or zero. A blood sample can be taken from the patient and then tested with this new testing kit based on the AAD fusion protein. After comparing to the standard curve (generated from standard solution plotted from known arginine concentration solutions), the exact arginine concentration of this blood sample of the patient can be measured. Therefore, this data helps monitor the progress of an arginine depletion treatment method. If the arginine level is too high (e.g. 200 micro-molar), more arginine depleting drug can be used on the patient to further keep the arginine at a lower or undetectable level so that the tumor can be inhibited by the systemic arginine depletion in the cancer patient.

Example 12B Testing Arginine Level in a Food Sample

For industrial or food manufacturing purposes, the arginine (amino acid) level of a particular food material or intermediate during the food processing step might need to be monitored and measured. This arginine testing kit by using the AAD fusion protein of the present invention can measure the exact arginine concentration of a food sample prepared in solution form in the laboratory. This testing kit can also be used in high throughput manner and applicable for industrial scale and mass production.

Example 12C Testing Arginine Level in Cell Culture

Nitric oxide (NO) is an important signaling molecule in cells and in the body. For many research projects on nitric oxide (NO) and cell culture studies, a lot of time a scientist would need to measure the amount or concentration of arginine (which is a substrate for making NO). This arginine testing kit by using the AAD fusion protein of the present invention can also be used for measuring the exact arginine concentration of any laboratory samples and/or analytical samples (e.g. for NO and cell culture studies). 

What is claimed is:
 1. A method of treating a cancer or arginine-dependent disease in a subject comprising administering a clinically effective amount of an albumin-binding deiminase fusion protein to the patient weekly or biweekly to reduce the availability of circulating arginine, wherein said albumin-binding arginine deiminase fusion protein comprises a first portion comprising one or two components selected from an albumin-binding domain, an albumin-binding peptide or an albumin-binding protein(s) fused to a second portion comprising arginine deiminase to form the albumin-binding arginine deiminase fusion protein, and one or more linker molecules; the first portion being positioned far from active site of the second portion by said linker molecule such that the albumin-binding arginine deiminase fusion protein retains the activity of arginine deiminase and binds serum albumin with neither function of one portion of the fusion protein being interfered with by the other portion of the fusion protein.
 2. The method of claim 1, wherein said cancer or arginine-dependent disease is argininosuccinate synthetase-negative.
 3. The method of claim 1, wherein said cancer consists essentially of pancreatic cancer, leukemia, melanoma, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer or brain cancer.
 4. The method of claim 1, wherein said albumin-binding arginine deiminase fusion protein further comprises a sequence selected from SEQ ID NO: 36, 37, 38, 39, 40, or
 41. 5. The method of claim 1, wherein the two components of the first portion are the same.
 6. The method of claim 1, wherein the two components of the first portion are different from each other.
 7. The method of claim 1, wherein said albumin-binding domain is SEQ ID NO: 46, 47, 48, or
 49. 8. The method of claim 1, wherein said albumin binding peptide is SEQ ID NO: 46, 47, 48, or
 49. 9. The method of claim 1, wherein the linker molecule comprises a sequence selected from SEQ ID NO: 50, 51, 52, 53, or serine-glycine-serine (SGS) amino acid sequence.
 10. The method of claim 1, wherein said albumin-binding arginine deiminase fusion protein further comprises at least one of Poly-N or a His tag.
 11. The method of claim 1, wherein the arginine deiminase is selected from arginine deiminase produced from a Mycoplasma, Lactococcus, Pseudomonas, Streptococcus, Escherichia, Mycobacterium or Bacillus microorganism.
 12. The method of claim 1, wherein the arginine deiminase is produced from Mycoplasma arginini, Lactococcus lactis, Bacillus licheniformis, Bacillus cereus, Mycoplasma arthritidis, Mycoplasma hominis, Streptococcus pyogenes, Streptococcus pneumoniae, Mycobacterium tuberculosis, Pseudomonas plecoglossicida, Pseudomonas putida, Pseudomonas aeruginosa, thermophilic Aspergillus fumigatus or a combination thereof.
 13. The method of claim 1, wherein said clinically effective amount of said albumin-binding deiminase fusion protein is 1.3 mg/kg/week and said subject is human.
 14. The method of claim 1, wherein said albumin-binding deiminase fusion protein is clinically effective in a pH range from 5.5 to 9.5.
 15. The method of claim 1, wherein said albumin-binding deiminase fusion protein is clinically effective at pH 7.4.
 16. The method of claim 1, wherein said albumin-binding deiminase fusion protein is clinically effective at pH 6.5.
 17. The method of claim 15, wherein said albumin-binding deiminase fusion protein has a specific activity of about 19 U/mg at pH 7.4.
 18. The method of claim 1, wherein said albumin-binding deiminase fusion protein is purified from both soluble and insoluble fractions of crude proteins.
 19. A method of producing an albumin-binding arginine deiminase fusion protein comprising reacting an arginine deiminase having a N-terminal cysteine residue with a reactive thioester at C-terminus of an albumin-binding domain so that the arginine deiminase and the albumin-binding domain are linked by a covalent bond.
 20. A method of producing an albumin-binding arginine deiminase fusion protein comprising reacting an albumin-binding domain having a N-terminal cysteine residue with a reactive thioester at C-terminus of an arginine deiminase so that the arginine deiminase and the albumin-binding domain are linked by a covalent bond.
 21. A method of producing an albumin-binding arginine deiminase fusion protein comprising using an amino acid sequence of SEQ ID NO: 42 or 43 and reacting an arginine deiminase having a N-terminal cysteine residue with a reactive thioester at C-terminus of an albumin-binding domain so that the arginine deiminase and the albumin-binding domain are linked by a covalent bond.
 22. A method of producing an albumin-binding arginine deiminase fusion protein comprising ligating a first portion and a second portion of the albumin-binding arginine deiminase fusion protein with a remaining portion of an intein-mediated protein.
 23. A kit for detecting of and measuring amount of arginine present in a sample comprising an albumin-binding deiminase fusion protein and a color reagent, said albumin-binding deiminase fusion protein comprising a first portion comprising one or two components selected from an albumin-binding domain, an albumin-binding peptide or an albumin-binding protein(s) fused to a second portion comprising arginine deiminase to form the albumin-binding arginine deiminase fusion protein, and one or more linker molecules; the first portion being positioned far from active site of the second portion by said linker molecule such that the albumin-binding arginine deiminase fusion protein retains the activity of arginine deiminase and binds serum albumin with neither function of one portion of the fusion protein being interfered with by the other portion of the fusion protein.
 24. The kit of claim 23, wherein said sample comprises blood samples from cancer patients, food samples, and analytical samples.
 25. The kit of claim 23, wherein said cancer comprises pancreatic cancer, leukemia, melanoma, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer.
 26. The kit of claim 23, wherein said albumin-binding arginine deiminase fusion protein further comprises a sequence selected from SEQ ID NO: 36, 37, 38, 39, 40, or
 41. 27. The kit of claim 23, wherein the two components of the first portion of said albumin-binding deiminase fusion protein are the same.
 28. The kit of claim 23, wherein the two components of the first portion of said albumin-binding deiminase fusion protein are different from each other.
 29. The kit of claim 23, wherein said albumin-binding domain or albumin binding peptide of said albumin-binding arginine deiminase fusion protein is SEQ ID NO: 46, 47, 48, or
 49. 30. The kit of claim 23, wherein the linker molecule of said albumin-binding arginine deiminase fusion protein comprises a sequence selected from SEQ ID NO: 50, 51, 52, 53, or serine-glycine-serine (SGS) amino acid sequence.
 31. The kit of claim 23, wherein said color reagent comprises an acidic ferric chloride solution and a diacetyl monoxime-thiosemicarbazide solution which are mixed with each other for measuring the amount of citrulline converted from arginine in said sample by said albumin-binding deiminase fusion protein with a pre-determined arginine deiminase activity.
 32. The kit of claim 31, wherein the arginine in said sample is incubated with said albumin-binding deiminase fusion protein, said color reagent and 10 mM sodium phosphate at pH 7.4 for 5 minutes at 37° C. to form a reaction mixture followed by heating at 100° C. for 5 minutes to develop into pink color.
 33. The kit of claim 32, wherein said pink color developed is read by a spectrophotometer at 540 nm in order to indicate the presence of and determine the amount of arginine in said sample by the following formula: one unit of arginine deiminase activity=1 μmol of arginine being converted to 1 μmol of citrulline per minute, and wherein said pre-determined arginine deiminase activity of said albumin-binding deiminase fusion protein at pH 7.4 and 37° C. is about 19 U/mg.
 34. The kit of claim 23, wherein said albumin-binding deiminase fusion protein is purified from both soluble and insoluble fractions of crude proteins. 